varenicline tartrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
varenicline tartrate: clinical details
Prescribing considerations
- Confirm adult smoking cessation as the licensed indication and offer behavioural support.
- Assess renal function where impairment is known or suspected; exposure rises as renal function declines.
- Review psychiatric history, seizure history, cardiovascular disease, pregnancy or breastfeeding, and concurrent stop-smoking treatments.
- Consider how smoking cessation may affect medicines influenced by tobacco-smoke enzyme induction.
- Warn about dizziness, somnolence, visual effects and rare transient loss of consciousness.
Contraindications and cautions
- Hypersensitivity to varenicline or any product excipient.
- Use caution with psychiatric illness, previous seizures or factors lowering seizure threshold, cardiovascular disease and renal impairment.
- The selected product is not recommended in end-stage renal disease or for paediatric patients.
Monitoring
- Changes in mood, behaviour, thinking or underlying psychiatric illness.
- New or worsening cardiovascular symptoms.
- Seizure occurrence.
- Renal function when clinically relevant.
- Tolerability, smoking status and withdrawal symptoms.
- Clinical effects or relevant tests for medicines affected by smoking cessation, including INR, glucose or plasma concentrations where appropriate.
Clinical pharmacology
Varenicline is a selective α4β2 nicotinic receptor partial agonist. It undergoes little metabolism and is eliminated mainly unchanged in urine, with low plasma-protein binding and little potential for cytochrome P450-mediated interactions.
Formulation and product differences
- The selected product is a light-blue, capsule-shaped, biconvex film-coated tablet intended to be swallowed whole.
- It is essentially sodium-free.
- Tablet appearance, excipients, packaging and storage requirements may differ between manufacturers; check the product-specific SmPC and leaflet.
varenicline tartrate preparations and strengths
Tablet
Route: Oral
Strengths: 0.5 mg, 0.5 mg + 1 mg, 1 mg
varenicline tartrate interactions
Varenicline itself has few clinically meaningful pharmacokinetic interactions, but stopping smoking can change the handling or effects of other medicines.
Theophylline or aminophylline
Stopping smoking may increase exposure, so clinical review and monitoring may be needed.
Warfarin
Varenicline does not directly alter warfarin, but smoking cessation may change anticoagulant requirements; review INR monitoring.
Insulin
Stopping smoking may alter insulin requirements, so glucose control should be reviewed.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.